Early prediction models for extended-spectrum β-lactamase-producing Escherichia coli infection in emergency department

A protocol for systematic review and meta analysis

Yiwu Zhou, MD, Shu Zhang, MD, PhD*

Abstract

Background: Resistance in gram-negative bacteria has gained great importance in recent decades and one reason is the rapid increase of extended spectrum β-lactamase (ESBL)-producing bacteria as a growing problem worldwide. The increasing proportion of ESBL-producing Enterobacteriaceae (ESBL-E) infections acquired in the emergency community is a new feature of ESBLs epidemiology. Early recognition of patients with extended-spectrum β-lactamase-producing Escherichia coli infection is important in the emergency department. To mitigate the burden on the healthcare system, while also providing the best possible care for patients, early recognition of the infection is needed.

Methods: For the acquisition of required data of eligible prospective/retrospective cohort study or randomized controlled trials (RCTs), we will search for publications from PubMed, Web of science, EMBASE, Cochrane Library, Google scholar. Two independent reviewers will read the full English text of the articles, screened and selected carefully, removing duplication. Then we evaluate the quality and analyses data by Review Manager (V.5.4). Results data will be pooled and meta-analysis will be conducted if there’s 2 eligible studies considered.

Results: This systematic review and meta-analysis will evaluate the value of the early prediction models for Extended-spectrum β-lactamase-producing E coli infection in emergency department.

Conclusions: This systematic review and meta-analysis will provide clinical evidence for predicting Extended-spectrum β-lactamase-producing E coli infection in emergency department, inform our understanding of the value of the predictive model in predicting Extended-spectrum β-lactamase-producing E coli infection in emergency department in the early stage. The conclusions drawn from this study may be beneficial to patients, clinicians, and health-related policy makers.

Study registration number: INPLASY202130049.

Abbreviations: ESBL = extended spectrum β-lactamase, ESBL-E = ESBL-producing Enterobacteriaceae.

Keywords: β-lactamase, escherichia coli, extended-spectrum, meta-analysis, prediction models, protocol, systematic review

1. Introduction

Antimicrobial resistance is an ecological problem that occurs worldwide and has been associated with increased resistance in both hospital-acquired and community-acquired infections. Resistance in gram-negative bacteria has gained great importance in recent decades and one reason is the rapid increase of extended spectrum β-lactamase (ESBL)-producing bacteria as a growing problem worldwide. High prevalence rates of ESBL-producing Enterobacteriaceae (ESBL-E) have been reported in Escherichia coli and Klebsiella pneumoniae. Moreover, ESBL presence in Enterobacteriaceae has been associated with high proportions of resistance to non-β-lactam classes of antibiotics.

The increasing proportion of ESBL-E infections acquired in the emergency community is a new feature of ESBLs epidemiology. The main infection sites of emergency ESBL-E are urinary tract infections and bloodstream infections. ESBLs are produced by E coli and K pneumoniae. Klebsiella has a high incidence in both hospital and community-acquired urinary tract infections which has become the main pathogen of community-acquired bloodstream infections and urinary tract infections.

The risk factors for ESBL-E infection in the emergency department mainly include advanced age, history of repeated use of antibacterial drugs, invasive procedures, hospital or nursing home residence history, immunosuppression, etc. Early recognition of ESBL-E infection is important in the emergency department.
recognition of patients with extended-spectrum β-lactamase-producing *E. coli* infection is important in the emergency department. To mitigate the burden on the healthcare system, while also providing the best possible care for patients, early recognition of the infection is needed. Prediction models that combine several variables or features to estimate the risk of people being infected from extended-spectrum β-lactamase-producing *E. coli* could assist medical staff in triaging patients when allocating limited healthcare resources.\cite{18-21} Models based scoring systems have been proposed and published in response to a call to share extended-spectrum β-lactamase-producing *E. coli* infection research findings rapidly and openly to inform the public health response and help save lives.\cite{22-24}

While up to now, no systematic review or meta-analysis has been performed on models for predicting extended-spectrum β-lactamase-producing *E. coli* infection. We aimed to systematically review and critically appraise currently available prediction models for extended-spectrum β-lactamase-producing *E. coli* infection.

## 2. Methods

### 2.1. Study registration

This systematic review was recorded in the international platform of registered systematic review and meta-analysis protocols (INPLASY) on March 15, 2021 with the registration number of INPLASY202130049 (doi:10.37766/inplasy.2021.3.0049). The protocol will follow the PRISMA protocols 2015 statement which is represented for Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA-P).\cite{23}

### 2.2. Eligibility criteria for study selection

We will collect all cross-sectional studies that predict or analyzed the patients with Extended-spectrum β-lactamase-producing *E. coli* infection in emergency department. The study includes adolescent participants, but children or pregnant women doesn’t meet the inclusion criteria. Animal studies, cadaver studies, comments, case reports, letters, protocols, guidelines, unpublished articles, and review papers will be excluded. No matter where the articles come from, we only review articles in English. Participants who are included in the articles should be diagnosed with Extended-spectrum β-lactamase-producing *E. coli* infection. This study will follow the PICOS principle that considering the eligibility criteria adopted in the population of the study, Intervention, Comparison, Result and Study design according to the details showed in the Table 1.

### 2.3. Search strategy

At first, the collection of bibliographic data will be made in the electronic databases: PubMed, Web of science, EMBASE, Cochrane Library, Google scholar. We use the available publications of the Extended-spectrum β-lactamase-producing *E. coli* infection systematic review for a list of keywords. The words are considered: Extended-spectrum β-lactamase-producing, *E. coli*, infection, emergency department, Grippe, prognostic, prediction, prediction model, regression, score, artificial intelligence, algorithm, deep learning, machine learning. We make the search terms by combining the words above:

#1 Extended-spectrum β-lactamase-producing, OR ESBL
#2 *Escherichia coli*, OR *E. coli*
#3 diagnostic OR imaging OR prognostic OR prognosis OR prediction OR prediction model OR mortality OR regression OR score OR artificial intelligence OR algorithm OR deep learning
OR machine learning
#4 emergency department OR ED OR emergency medical service
OR emergency room
#5 English NOT animal NOT children NOT child NOT pediatric
NOT pediatrics NOT pregnant NOT pregnant woman NOT
pregnant women NOT pregnancy NOT gravidity
NOT maternal
#1 AND #2 AND #3 AND #4 AND #5

### 2.4. Selection of studies

The preliminary documents are obtained by looking through the titles and abstract, removing the duplications. For the further screening, 2 reviewers will read the full text of the articles which are selected carefully, removing the unsatisfied articles and sending an email to ask author for the full text or the details. Any disagreements will be arbitrated by a third reviewer. The whole process of study selection is presented in the flow chart following the PRISMA principle (Fig. 1).

### 2.5. Data extraction and management

Two of three reviewers will extract the data from eligible studies, putting them into the pre-specified form that we make in advance: author information, study area, study time, study type, study design, setting of study, sample size, participant characteristics, primary and secondary outcomes (needing for mechanical ventilation, needing for ICU care, or dead), AUC (Area Under Curve). Another researcher will solve the divergence between the first two reviewers.

### 2.6. Assessment of risk of bias

The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment tool will be used for conducting an appraisal of the studies’ methodological quality.

---

**Table 1.**

| PICOS             | Abbreviation | Elements                                                                 |
|-------------------|--------------|--------------------------------------------------------------------------|
| Patient population| P            | Adult                                                                     |
| Intervention/Exposure | I           | Patients with Extended-spectrum β-lactamase-producing *E. coli* infection |
| Comparison/control | C           | Patients without Extended-spectrum β-lactamase-producing *E. coli* infection |
| Outcome           | O            | Risk of infection due to Extended-spectrum β-lactamase-producing *E. coli* |
| Study design      | S            | Prospective/retrospective cohort study, RCTs                             |

*C = Comparison or control, I = Intervention or Exposure, O = outcome, P = patient population, S = study design.*
Every selected study will be evaluated by 2 reviewers independently, a third one as a consulter. The GRADE evaluation system included bias risk; heterogeneity; indirectness; imprecision; publication bias. And each level of evidence is divided into “very”, “low”, “moderate”, or “high” judgment.

2.7. Data synthesis and analysis
For qualified articles, we would like to combine the collected data according to characteristics of eligible trials. In line with the Cochrane guideline, we will express risk ratio with 95% confidence intervals (95%CI) using fixed effect model. Besides the random effect model will be used for continuous outcomes because of clinical heterogeneity. Statistical heterogeneity will be investigated using $\chi^2$ test and I$^2$ statistic ($<25\%$, no heterogeneity; 25%–50%, moderate heterogeneity; and >50%, strong heterogeneity). We will assess possible publication bias using the Egger funnel plot. All data will be performed by using Review Manager (RevMan version 5.4.0) software and $P$ value < .5 will be considered statistically significant.

2.8. Ethics and dissemination
For the development of this study, approval of ethics and consent is not necessary because it is a systematic review that will use secondary studies. Ethical approval is unnecessary because this is a literature-based study.

3. Discussion
To our best knowledge, this is the first systematic review and meta-analysis to investigate prediction models for Extended-spectrum $\beta$-lactamase-producing $E. coli$ infection. Five English databases will be searched to avoid missing any potential eligible studies.

Prognostic models for Extended-spectrum $\beta$-lactamase-producing $E. coli$ infection are available and they all appear to show good to excellent discriminative performance. However, some models are at high risk of bias, mainly because of nonrepresentative selection of control patients, exclusion of patients who had not experienced the event of interest by the end of the study, and model overfitting. Therefore, their performance estimates are likely to be optimistic and misleading. Future studies should address these concerns. Sharing data and expertise for development, validation, and updating of Extended-spectrum $\beta$-lactamase-producing $E. coli$ infection related prediction models is urgently needed.

Author contributions
Conceptualization: Yiwu Zhou.
References

[1] Chioro A, Coll-Seck AM, Hoie B, et al. Antimicrobial resistance: a priority for global health action. Bull World Health Organ 2013;91:439.

[2] Cerco E, Detelzweig SB, Sherman BM, et al. Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist 2016;22:412–31.

[3] Arias Ramos D, Hoyos Pulgarin JA, Moreno Gomez GA, et al. Geographic mapping of Enterobacteriaceae with extended-spectrum beta-lactamase (ESBL) phenotype in Pereira, Colombia. BMC Infect Dis 2020;20:540.

[4] Chaisathaphol T, Chayakulkeeree M. Epidemiology of infections caused by multidrug-resistant gram-negative bacteria in adult hospitalized patients at Siriraj Hospital. J Med Assoc Thai 2014;97(Suppl 3):S33–45.

[5] Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy 2015;35:949–62.

[6] Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015;90:395–403.

[7] Blom A, Ahl J, Mansson F, et al. The prevalence of ESBL-producing Enterobacteriaceae in a nursing home setting compared with elderly living at home: a cross-sectional comparison. BMC Infect Dis 2016;16:111.

[8] Martinez JA. [Approach to directed therapy after knowledge of the isolate: carbapenemase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii]. Rev Esp Quinioter 2016;26(Suppl 1):31–4.

[9] Jones RN, Guzman-Blanco M, Gales AC, et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz J Infect Dis 2013;17:672–81.

[10] Boyle DP, Zembower TR. Epidemiology and management of emerging drug-resistant Gram-negative bacteria: extended-spectrum beta-lactamases and beyond. Urol Clin North Am 2015;42:493–505.

[11] Lin JN, Chen YH, Chang LL, et al. Clinical characteristics and outcomes of patients with extended-spectrum beta-lactamase-producing bacteremias in the emergency department. Intern Emerg Med 2011;6:547–55.

[12] Kunz AN, Brook I. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy 2010;56:492–500.

[13] Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremias. J Infect 2014;69:216–25.

[14] Lin JN, Tsai YS, Lai CH, et al. Risk factors for mortality of bacteremic patients in the emergency department. Acad Emerg Med 2009;16:749–55.

[15] Armand-Lefevre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013;57:1488–95.

[16] Kim YJ, Jung SM, Kang J, et al. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. Intern Emerg Med 2019;14:433–40.

[17] Freeman JT, McBride SJ, Nisbet MS, et al. bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. Int J Infect Dis 2012;16:e371–4.

[18] Johnson SW, Anderson DJ, May DB, et al. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum beta-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol 2013;34:885–92.

[19] Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011;55:1485–90.

[20] Miller BM, Johnson SW. Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: development of a bedside clinical score for risk assessment. Am J Infect Control 2016;44:134–7.

[21] Gara M, Paasch F, Goossens H, et al. Current trends in culture-based and molecular detection of extended-spectrum-beta-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2012;50:1140–6.

[22] Lee CH, Chu FY, Hsieh CC, et al. A simple scoring algorithm predicting extended-spectrum beta-lactamase producers in adults with community-onset monomicrobial Enterobacteriaceae bacteremia: matters of frequent emergency department users. Medicine (Baltimore) 2017;96:e6648.

[23] Bassetti M, Carmellati A, Pegliu M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti Infect Ther 2017;15:55–65.

[24] Froding I, Valik JK, Bolinder L, et al. Prediction of bloodstream infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in patients with suspected community-onset sepsis. Int J Antimicrob Agents 2019;53:820–9.

[25] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.